Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective mRNA translation determines adaptative mutability of melanoma cells to anti-BRAF/MEK combination therapy.

EMBO molecular medicine - 1 Aug 2026

Fabbri Lucilla, Lagadec Lucie, Guérin Eva, Lecourt Hélène, Baille Dorothée, Besse Laetitia, Messaoudi Cédric, Désaubry Laurent, Abou-Hamdan Hussein, Roy Sévérine, Lombard Bérangère, Loew Damarys, Scoazec Jean-Yves, Robert Caroline, Vagner Stéphan

Abstract excerpt

During their inevitable evolution towards acquired resistance to anti-cancer targeted therapies, cancer cells adopt distinct gene expression profiles that allow them to transiently adapt to and tolerate the treatment. Cancer cells surviving therapy can increase their mutation rate, enhancing the likelihood of acquiring resistance-conferring mutations and evolving into resistant cells. Here we show that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Melanoma

Share to Protein Biosynthesis

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to RNA, Messenger

Source

Open in PubMed Open full text

Identifiers

PMID: 42477455
DOI: 10.1038/s44321-026-00479-5
PMCID: PMC13470486

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective mRNA translation determines adaptative mutability of melanoma cells to anti-BRAF/MEK combination therapy.PMID 42477455Read ↗

An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells.Semantic proximity Read ↗

Adaptive post-transcriptional reprogramming of metabolism limits response to targeted therapy in BRAF <sup>V600</sup> melanomaSemantic proximity Read ↗

Rapidly induced drug adaptation mediates escape from BRAF inhibition in single melanoma cellsSemantic proximity Read ↗

Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma.Semantic proximity Read ↗

Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.Semantic proximity Read ↗

Adaptive mutability of colorectal cancers in response to targeted therapiesSemantic proximity Read ↗

Drug tolerance to target therapy in melanoma revealed at single cell level: What next?Semantic proximity Read ↗

A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancerSemantic proximity Read ↗

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.Semantic proximity Read ↗

tRNA modifications are required for stress granule formation and melanoma metastasisSemantic proximity Read ↗

Unblinding the watchmaker: cancer treatment and drug design in the face of evolutionary pressure.Semantic proximity Read ↗

The unfolded protein response impacts melanoma progression by enhancing FGF expression and can be antagonized by a chemical chaperone.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.